NEW DELHI: Controversy over AstraZeneca plc's covid-19 vaccine clinical trial may allow Serum Institute of India to only receive regulatory clearance for its full-dose regimen which had 62% efficacy, but that may still help India and other resource-constrained countries combat the pandemic.Serum Institute is manufacturing up to one billion doses of the vaccine, which has been jointly developed by AstraZeneca and University of Oxford.
The Pune-based firm will market the vaccine under its brand Covishield after receiving regulatory approval.“You may have a vaccine of 95% efficacy but you can give it to less than 50% of people who should be getting it, then that’s no good.